Gilead Sciences, Inc.
145.65USD
-0.9900 (-0.68%)
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | 27.3B | 27.1B | 28.8B | 29.4B | 30.7B | 32.7B |
| Q1 | 6.6B | 6.4B | 6.7B | 6.7B | 7.0B | — |
| Q2 | 6.3B | 6.6B | 7.0B | 7.1B | 7.8B | — |
| Q3 | 7.0B | 7.1B | 7.5B | 7.8B | 7.8B | — |
| Q4 | 7.4B* | 7.1B* | 7.6B* | 7.9B* | 8.1B | — |
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | 3.64 | 4.50 | .380 | 6.78 | -.431 | 9.89 |
| Q1 | .020 | .800 | -3.34 | 1.04 | 1.61 | — |
| Q2 | .910 | .830 | 1.29 | 1.56 | -8.45 | — |
| Q3 | 1.42 | 1.73 | 1.00 | 2.43 | 2.14 | — |
| Q4 | 1.30* |
Fiscal period: Reported, Estimated. Reported figures: SEC filings (EDGAR). Estimates are sell-side consensus for periods that have not reported. Cells marked * were synthesized from the annual filing less the year-to-date figures, because the quarter was not filed on its own. Earnings per share are restated onto today's share basis, so a period before a stock split is comparable with the ones after it.
| 1.14* |
| 1.42* |
| 1.74* |
| 2.19 |
| — |